ISO TR 22442-4-2010 PDF

Full title and description

ISO/TR 22442-4:2010 — Medical devices utilizing animal tissues and their derivatives — Part 4: Principles for elimination and/or inactivation of transmissible spongiform encephalopathy (TSE) agents and validation assays for those processes. This Technical Report provides guidance and practical suggestions for designing and conducting validation assays to assess whether manufacturing and processing steps for non-viable animal-derived materials reduce the risk of iatrogenic transmission of TSE agents.

Abstract

ISO/TR 22442-4:2010 summarizes current principles and state-of-the-art approaches for elimination and/or inactivation of transmissible spongiform encephalopathy (TSE) agents in medical-device manufacturing that uses non‑viable animal tissues or derivatives. It gives recommendations on designing and interpreting validation assays, discusses appropriate surrogate agents and controls, and clarifies applicability with respect to the rest of the ISO 22442 series and related standards. The report does not cover human‑origin tissues and does not require validation for materials listed as “negligible risk” in Annex C of ISO 22442-1:2007.

General information

• Status: Published (Technical Report; confirmed on review).
• Publication date: December 2010 (Edition 1, 2010).
• Publisher: International Organization for Standardization (ISO).
• ICS / categories: 11.100.20 — Biological evaluation of medical devices and related products.
• Edition / version: Edition 1 (2010).
• Number of pages: 14.

Scope

This Technical Report offers practical guidance intended to help manufacturers, testing laboratories and regulators design and conduct validation assays that address the potential for TSE-agent contamination and to assess whether specific processing steps eliminate and/or inactivate those agents. It applies to medical devices manufactured using non‑viable animal tissues and their derivatives. It does not cover tissues of human origin, and it does not imply validation is required for materials already identified as having negligible TSE risk (see Annex C of ISO 22442-1:2007). The document complements and clarifies provisions in other parts of the ISO 22442 series and related ISO documents addressing sterilization and risk management.

Key topics and requirements

• Principles for elimination and inactivation of TSE agents in processing of animal‑derived materials.
• Guidance on designing validation assays to demonstrate removal/inactivation efficacy.
• Selection and use of appropriate surrogate agents, assay controls and detection limits.
• Sampling, spiking and recovery procedures for validation experiments.
• Interpretation of validation data, including limits of detection and log‑reduction metrics.
• Consideration of material variability, process scale‑up and worst‑case conditions.
• Documentation, traceability and reporting expectations for validation studies.
• Relationship to risk management decisions and when validation is required.

Typical use and users

Primary users include medical‑device manufacturers that incorporate animal‑derived tissues or derivatives, contract manufacturing and testing laboratories that perform validation studies, regulatory affairs and quality assurance professionals preparing submissions or technical files, and standards committees. The report is used when assessing process steps (chemical treatments, enzymatic digestion, filtration, etc.) that may reduce or inactivate TSE agents and when preparing validation protocols and reports for regulatory review.

Related standards

ISO/TR 22442-4:2010 is part of the ISO 22442 series and should be used alongside: ISO 22442-1 (application of risk management), ISO 22442-2 (controls on sourcing, collection and handling), and ISO 22442-3 (validation of elimination/inactivation of viruses and TSE agents). It is also complementary to ISO 14160 (sterilization considerations for devices incorporating animal‑origin materials) and the ISO 10993 biological evaluation series where applicable. National regulatory guidance documents (for example, agency guidance on animal‑derived materials) commonly reference this series.

Keywords

TSE, transmissible spongiform encephalopathy, prion, inactivation, elimination, validation assay, animal‑derived materials, medical devices, bioburden control, ISO 22442, risk management.

FAQ

Q: What is this standard?

A: ISO/TR 22442-4:2010 is a Technical Report providing guidance on principles and validation assays for elimination and/or inactivation of transmissible spongiform encephalopathy (TSE) agents in the manufacture of medical devices that use non‑viable animal tissues or their derivatives.

Q: What does it cover?

A: It covers conceptual and practical recommendations for designing, performing and interpreting validation assays intended to demonstrate the effectiveness of manufacturing or processing steps to remove or inactivate TSE agents. It addresses surrogate selection, assay controls, sampling and interpretation, but does not set prescriptive pass/fail values for every case.

Q: Who typically uses it?

A: Manufacturers of medical devices containing animal‑derived components, contract testing laboratories, quality and regulatory professionals, and standards authors use this report when planning and documenting TSE‑related validation activities.

Q: Is it current or superseded?

A: ISO/TR 22442-4 was published in December 2010 (Edition 1). As a Technical Report, it has been reviewed periodically; users should check the latest national or ISO catalogue entries or regulatory guidance to confirm whether a newer edition or replacement has been published before relying on it for current regulatory submissions.

Q: Is it part of a series?

A: Yes — it is Part 4 of the ISO 22442 series (medical devices utilizing animal tissues and their derivatives) and is intended to be used together with Parts 1–3 and with related standards such as ISO 14160 and relevant parts of the ISO 10993 series.

Q: What are the key keywords?

A: TSE, prion, inactivation, elimination, validation assay, animal‑derived materials, medical devices, bioburden, ISO 22442.